Topoisomerase I inhibitors: review and update.

This review presents a summary of preclinical and clinical data on the topoisomerase I (topo I) inhibitors that are under clinical development. To date, all of the topo I inhibitors that have been clinically evaluated are analogues of camptothecin, an extract of the Chinese tree Camptotheca acuminata. The therapeutic development of camptothecin was initially limited […]

Mechanism of action of camptothecin.

Camptothecin (CPT) class of compounds has been demonstrated to be effective against a broad spectrum of tumors. Their molecular target has been firmly established to be human DNA topoisomerase I (topo I). CPT inhibits topo I by blocking the rejoining step of the cleavage/religation reaction of topo-I, resulting in accumulation of a covalent reaction intermediate, […]

SBIR-Funded Alliance to Conquer the Cold-Chain

July 20, 2018 TopoGEN was featured in the local press in order to showcase our collaboration with Nanoly Bioscience based out of Boulder.  Nanoly has developed a polymer-based cage (the NanoShield) that can protect labile products from fluctuations in temperature and possibly obviate need for expensive dry ice transit around the world.  TopoGEN is going to field […]

0
    0
    Your Cart
    Your cart is emptyReturn to Shop